S. Couraud
349 works · 5,723 citations · h-index 28
Top works
- Lung cancer in never smokers – A review
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
- Negative Predictive Value of Transthoracic Core-Needle Biopsy
- From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
- Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
- 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
- ESR/ERS statement paper on lung cancer screening
- Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
- Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
- BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
- Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
- Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
- ESR/ERS statement paper on lung cancer screening
- Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes
- Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
- Lung Cancer May Increase Serum Procalcitonin Level
- Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
- Implementing Lung Cancer Screening in Europe: Taking a Systems Approach